Chemokines represent a superfamily of immune-modulatory small protein molecules that regulate leukocyte migration to inflammatory sites through their chemoattractant and cell signaling properties. This review focuses on the immunological functions of the CCR6 chemokine receptor and is chemokine ligand, CCL20, that contribute to it role in inflammation in human psoriasis.
Methods
Peer-reviewed relevant articles are searched and selected from 2000 to 2022 using the search engines including PubMed and Google Scholar.
Results
After selectively reviewing and evaluating over seventy articles, a comprehensive overview on the immunology of CCL20-CCR6 axis in psoriasis and psoriatic arthritis, the X-ray crystal structures of CCL20 monomers, and the potential of developing clinical therapies targeting this axis is summarized.
Conclusions
Over the past decade, preclinical studies carried out in animal models of psoriasis involving agents targeting CCL20-CCR6 axis have yielded promising results. Other studies that this axis may play a role in a number of other autoimmune diseases, including rheumatoid arthritis, suggesting a rationale for further investigation into this key signaling/migratory pathway.
ParisiRIskandarIYKKontopantelisE, et al.National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. BMJ. 2020;369:m1590.
Oliveira MdeFRocha BdeODuarteGV. Psoriasis: Classical and emerging comorbidities. An Bras Dermatol. 2015;90:9-20.
4.
OgdieAWeissP. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:545-568.
5.
LangleyRGElewskiBELebwohlM, et al.Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371:326-338.
6.
GriffithsCEMStroberBEvan de KerkhofP, et al.Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118-128.
7.
BilalJBerlinbergABhattacharjeeSTrostJRiazIBKurtzmanDJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018;29:569-578.
8.
DeodharAGottliebABBoehnckeWH, et al.Efficacy and safety of guselkumab in patients with active psoriatic arthritis: A randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391:2213-2224.
9.
McInnesIBKavanaughAGottliebAB, et al.Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780-789.
10.
McInnesIBMeasePJKirkhamB, et al.Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137-1146.
11.
CharoIFRansohoffRM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610-621.
12.
MabuchiTChangTWQuinterSHwangST. Chemokine receptors in the pathogenesis and therapy of psoriasis. J Dermatol Sci. 2012;65:4-11.
13.
SchutyserEStruyfSVan DammeJ. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14:409-426.
14.
LeeAYSEriRLyonsABGrimmMCKornerH. CC chemokine ligand 20 and its cognate receptor CCR6 in mucosal T cell immunology and inflammatory bowel disease: Odd couple or axis of evil?Front Immunol. 2013;4:194.
15.
HarperEGGuoCRizzoH, et al.Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129:2175-2183.
16.
ReibmanJHsuYChenLCBleckBGordonT. Airway epithelial cells release MIP-3alpha/CCL20 in response to cytokines and ambient particulate matter. Am J Respir Cell Mol Biol. 2003;28:648-654.
17.
MeissnerAZillesOVaronaR, et al.CC chemokine ligand 20 partially controls adhesion of naive B cells to activated endothelial cells under shear stress. Blood. 2003;102:2724-2727.
18.
YamazakiTYangXOChungY, et al.CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol. 2008;181:8391-8401.
19.
SamaniegoRGutierrez-GonzalezAGutierrez-SeijoA, et al.CCL20 expression by tumor-associated macrophages predicts progression of human primary cutaneous melanoma. Cancer Immunol Res. 2018;6:267-275.
20.
ScapiniPLaudannaCPinardiC, et al.Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19. Eur J Immunol. 2001;31:1981-1988.
21.
FurueKItoTTanakaY, et al.Cyto/chemokine profile of in vitro scratched keratinocyte model: Implications of significant upregulation of CCL20, CXCL8 and IL36G in Koebner phenomenon. J Dermatol Sci. 2019;94:244-251.
22.
SibartieSO’HaraAMRyanJ, et al.Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria. BMC Immunol. 2009;10:54.
23.
LeeAYSPhanTKHulettMDKornerH. The relationship between CCR6 and its binding partners: Does the CCR6-CCL20 axis have to be extended?Cytokine. 2015;72:97-101.
24.
SinghSPZhangHHFoleyJFHedrickMNFarberJM. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol. 2008;180:214-221.
25.
KitamuraKFarberJMKelsallBL. CCR6 marks regulatory T cells as a colon-tropic, IL-10-producing phenotype. J Immunol. 2010;185:3295-3304.
26.
KondoTTakataHTakiguchiM. Functional expression of chemokine receptor CCR6 on human effector memory CD8+ T cells. Eur J Immunol. 2007;37:54-65.
27.
KimTGJeeHFuentes-DuculanJ, et al.Dermal clusters of mature dendritic cells and T cells are associated with the CCL20/CCR6 chemokine system in chronic psoriasis. J Invest Dermatol. 2014;134:1462-1465.
28.
LeeAYSKornerH. The CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology. Immunobiology. 2019;224:449-454.
29.
HedrickMNLonsdorfASHwangSTFarberJM. CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets. 2010;14:911-922.
30.
KulkarniNMeiteiHTSonarSA, et al.CCR6 signaling inhibits suppressor function of induced-Treg during gut inflammation. J Autoimmun. 2018;88:121-130.
31.
ShenXZhangHXieH, et al.Reduced CCR6(+)IL-17A(+)Treg cells in blood and CCR6-dependent accumulation of IL-17A(+)Treg cells in lungs of patients with allergic asthma. Front Immunol. 2021;12:710750.
32.
ItoTCarsonWFt.CavassaniKAConnettJMKunkelSL. CCR6 as a mediator of immunity in the lung and gut. Exp Cell Res. 2011;317:613-619.
33.
ElguetaRMarksENowakE, et al.CCR6-dependent positioning of memory B cells is essential for their ability to mount a recall response to antigen. J Immunol. 2015;194:505-513.
34.
SuanDKrautlerNJMaagJLV, et al.CCR6 defines memory B cell precursors in mouse and human germinal centers, revealing light-zone location and predominant low antigen affinity. Immunity. 2017;47:1142-1153.e4.
35.
KleistABGetschmanAEZiarekJJ, et al.New paradigms in chemokine receptor signal transduction: Moving beyond the two-site model. Biochem Pharmacol. 2016;114:53-68.
36.
LuftJRCollinsRJFehrmanNALauricellaAMVeatchCKDeTittaGT. A deliberate approach to screening for initial crystallization conditions of biological macromolecules. J Struct Biol. 2003;142:170-179.
37.
VonrheinCFlensburgCKellerP, et al.Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D Biol Crystallogr. 2011;67:293-302.
38.
ChenVBArendallWB3rdHeaddJJ, et al.MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66:12-21.
39.
DavisIWLeaver-FayAChenVB, et al.MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007;35:W375-W383.
40.
WedemeyerMJMahnSAGetschmanAE, et al.The chemokine X-factor: Structure-function analysis of the CXC motif at CXCR4 and ACKR3. J Biol Chem. 2020;295:13927-13939.
41.
ChevigneAFievezVSchmitJCDerooS. Engineering and screening the N-terminus of chemokines for drug discovery. Biochem Pharmacol. 2011;82:1438-1456.
GetschmanAEImaiYLarsenO, et al.Protein engineering of the chemokine CCL20 prevents psoriasiform dermatitis in an IL-23-dependent murine model. Proc Natl Acad Sci U S A. 2017;114:12460-12465.
44.
RiuttaSJLarsenOGetschmanAERosenkildeMMHwangSTVolkmanBF. Mutational analysis of CCL20 reveals flexibility of N-terminal amino acid composition and length. J Leukoc Biol. 2018;104:423-434.
45.
ProudfootAEIHandelTMJohnsonZ, et al.Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A. 2003;100:1885-1890.
46.
VeldkampCTSeibertCPetersonFC, et al.Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal. 2008;1:ra4.
47.
DruryLJZiarekJJGravelS, et al.Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc Natl Acad Sci U S A. 2011;108:17655-17660.
48.
Perez-CanadillasJMZaballosA, et al.NMR solution structure of murine CCL20/MIP-3alpha, a chemokine that specifically chemoattracts immature dendritic cells and lymphocytes through its highly specific interaction with the beta-chemokine receptor CCR6. J Biol Chem. 2001;276:28372-28379.
49.
ChanDIHunterHNTackBFVogelHJ. Human macrophage inflammatory protein 3alpha: Protein and peptide nuclear magnetic resonance solution structures, dimerization, dynamics, and anti-infective properties. Antimicrob Agents Chemother. 2008;52:883-894.
50.
HooverDMBoulegueCYangD, et al.The structure of human macrophage inflammatory protein-3alpha/CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins. J Biol Chem. 2002;277:37647-37654.
51.
MalikZATackBF. Structure of human MIP-3alpha chemokine. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006;62:631-634.
52.
WasilkoDJJohnsonZLAmmiratiM, et al.Structural basis for chemokine receptor CCR6 activation by the endogenous protein ligand CCL20. Nat Commun. 2020;11:3031.
53.
LowesMASuarez-FarinasMKruegerJG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-255.
54.
MabuchiTTakekoshiTHwangST. Epidermal CCR6+ γδ T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J Immunol. 2011;187:5026-5031.
55.
VillanovaFFlutterBTosiI, et al.Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol. 2014;134:984-991.
56.
Dyring-AndersenBGeislerCAgerbeckC, et al.Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin. Br J Dermatol. 2014;170:609-616.
57.
LyndeCWPoulinYVenderRBourcierMKhalilS. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71:141-150.
58.
DianiMGalassoMCozziC, et al.Blood to skin recirculation of CD4(+) memory T cells associates with cutaneous and systemic manifestations of psoriatic disease. Clin Immunol. 2017;180:84-94.
59.
LaggnerUDi MeglioPPereraGK, et al.Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol. 2011;187:2783-2793.
60.
KitamuraKFarberJMKelsallBL. CCR6 marks regulatory T cells as a colon-tropic, IL-10-producing phenotype. J Immunol. 2010;185:3295-3304.
61.
HedrickMNLonsdorfASShirakawaAK, et al.CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest. 2009;119:2317-2329.
62.
MabuchiTSinghTPTakekoshiT, et al.CCR6 is required for epidermal trafficking of γδ-T cells in an IL-23-induced model of psoriasiform dermatitis. J Invest Dermatol. 2013;133:164-171.
63.
HarperEGGuoCRizzoH, et al.Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129:2175-2183.
64.
WangMZhangSZhengG, et al.Gain-of-function mutation of Card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A. Immunity. 2018;49:66-79.e5.
65.
JordanCTCaoLRobersonED, et al.PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90:784-795.
66.
DianiMCascianoFMarongiuL, et al.Increased frequency of activated CD8(+) T cell effectors in patients with psoriatic arthritis. Sci Rep. 2019;9:10870.
67.
HomeyBDieu-NosjeanMCWiesenbornA, et al.Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol. 2000;164:6621-6632.
68.
DavisonSCBallsdonAAllenMHBarkerJN. Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques. Exp Dermatol. 2001;10:280-285.
69.
RaoDAGurishMFMarshallJL, et al.Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542:110-114.
70.
LinJYuYMaJRenCChenW. PD-1+CXCR5-CD4+T cells are correlated with the severity of systemic lupus erythematosus. Rheumatology (Oxford). 2019;58:2188-2192.
71.
LiuWZhouXWangAMaJBaiY. Increased peripheral helper T cells type 17 subset correlates with the severity of psoriasis vulgaris. Immunol Lett. 2021;229:48-54.
72.
HirotaKYoshitomiHHashimotoM, et al.Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 2007;204:2803-2812.
73.
ShiZGarcia-MelchorEWuX, et al.Differential requirement for CCR6 in IL-23-mediated skin and joint inflammation. J Invest Dermatol. 2020;140:2386-2397.
74.
ShiZGarcia-MelchorEWuX, et al.Targeting the CCR6/CCL20 axis in entheseal and cutaneous inflammation. Arthritis Rheumatol. 2021;73:2271-2281.
75.
SteelKJASrenathanURidleyM, et al.Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17A+CD8+ T cells in psoriatic arthritis. Arthritis Rheumatol. 2020;72:435-447.
76.
LeijtenEFvan KempenTSBoesM, et al.Brief report: Enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid. Arthritis Rheumatol. 2015;67:2673-2678.
77.
CelisRPlanellNFernandez-SueiroJL, et al.Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther. 2012;14:R93.
78.
AbjiFPollockRALiangKChandranVGladmanDD. Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis. Clin Exp Rheumatol. 2018;36:486-489.
79.
RobertRAngCSunG, et al.Essential role for CCR6 in certain inflammatory diseases demonstrated using specific antagonist and knockin mice. JCI Insight. 2017;2:e94821.
80.
CampbellJJEbsworthKErtlLS, et al.IL-17-secreting γδ T cells are completely dependent upon CCR6 for homing to inflamed skin. J Immunol. 2017;199:3129-3136.
81.
Daniel DairaghiPZLeletiMBerahovichR, et al.Inhibition of Chemokine Receptors CCR1 and CCR6 as Promising Therapies for Autoimmune Diseases Such as Rheumatoid Arthritis and Psoriasis. ACR/ARHP Annual Meeting; 2013, Abstract No 1792.
82.
CampbellJJEbsworthKErtlLS, et al.Efficacy of chemokine receptor inhibition in treating IL-36α-induced psoriasiform inflammation. J Immunol. 2019;202:1687-1692.
83.
LeeAYSKornerH. CCR6 and CCL20: Emerging players in the pathogenesis of rheumatoid arthritis. Immunol Cell Biol. 2014;92:354-358.
84.
KaeleyGSEderLAydinSZGutierrezMBakewellC. Enthesitis: A hallmark of psoriatic arthritis. Semin Arthritis Rheum. 2018;48:35-43.
85.
HsuLArmstrongAW. Anti-drug antibodies in psoriasis: A critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol. 2013;9:949-958.
86.
BoumaGZamunerSHicksK, et al.CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6(+) cells in an experimental suction blister. Br J Clin Pharmacol. 2017;83:1976-1990.
87.
AdamsPDAfoninePVBunkocziG, et al.PHENIX: A comprehensive python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66:213-221.
